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Group Chairs Urge NCI To Limit Authority
Of Committees That Rule on Trial Funding
Guest  Editorial:
Patenting Nature: What Ruling in Myriad Case
Means for Biotechnology and DNA Diagnostics
By  Robert  Cook-­Deegan  
The  author  is  the  director  of  the  Center  for  Genome  Ethics,  Law  and  
Policy  at  the  Duke  University  Institute  for  Genome  Sciences  and  Policy.  He  
is  a  visiting  researcher  at  Fondation  Brocher  of  Switzerland.
On  July  29,  the  U.S.  Court  of  Appeals  for  the  Federal  Circuit  (CAFC)  
handed  down  its  long-­awaited  ruling  about  the  patent  lawsuit  brought  against  
0\ULDG*HQHWLFVDQGWKH863DWHQWDQG7UDGHPDUN2I¿FHE\DJURXSRI
more  than  20  plaintiffs.  
The  lawsuit  has  been  coordinated  and  argued  by  the  American  Civil  
Liberties  Union  and  the  Public  Patent  Foundation.  
First,  some  background,  then  an  explanation  of  what  the  court  ruled—
VRPHGLVFXVVLRQRIZK\WKLVFDVHPDWWHUV²DQG¿QDOO\DZRUGRQSRVVLEOH
next  steps.
For  those  in  biotechnology  and  those  who  eat  and  live  in  patent  law,  
Dorothy  clicked  her  heels  three  times  and  we’re  back  in  Kansas  again,  where  
high  patent  fences  protect  valuable  protein  therapeutics,  vaccines  and  other  
biologics.  If  you  do  DNA  diagnostics  for  a  living,  however,  the  storm  is  not  
over—and  you  can’t  be  sure  whether  your  house  has  landed  on  a  good  witch  
or  a  bad  one.  
By  Paul  Goldberg
The  chairs  of  clinical  trials  cooperative  groups  urged  NCI  to  change  
the  way  it  reviews  and  prioritizes  clinical  trials.
In   a   “white  paper,”   ten  group  chairs—those   left   standing   and   those  
whose  groups  have  been  reorganized  out  of  existence—asked  the  institute  
to   limit   the   authority   of   steering   committees   that   critics   say   are   causing  
XQQHFHVVDU\GHOD\VLQWKH¿QDOVWDJHVRISURWRFROUHYLHZ
The   letter   from   the  group  chairs   is  notable,  because   it   focuses  on  a  
debate  over  an  obscure  but  crucially  important  process  that  determines  which  
clinical  trials  get  funded  by  NCI.
NCI  operates  11  steering  committees,  where  review  is  conducted  by  
groups  of  20  to  25  people,  who  typically  meet  monthly  by  phone  and  once  
or  twice  a  year  in  person.  According  to  critics,  the  committees  are  slow  and  
prone  to  byzantine  exercises  of  academic  politics.
Over  the  past  15  years,  NCI  has  tried  three  approaches  to  protocol  review  
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There  may  be  a  bit  further  to  walk  on  the  yellow  
brick  road,  with  another  stop  at  the  CAFC  or  the  U.S.  
Supreme  Court  before  Dorothy  discovers  the  way  home.  
After  a  district  court  sent  you  to  Oz,  three  different  
MXGJHVKDYHJLYHQ\RXFOHDUGLUHFWLRQVEXWWKHLU¿QJHUV
point  in  different  directions  on  the  crucial  question  of  
whether   naturally   occurring  DNA   sequences   can   be  
patented.  
But  enough  about  Dorothy.
Myriad  Genetics   is   in   a  much   stronger   patent  
position   now   than   it   was   last   Thursday,   but   also  
weaker   than  before   the  case  began.  If   this  ruling  had  
set  expectations  in  1998,  Myriad  would  certainly  have  
KDGSDWHQWULJKWVVXI¿FLHQWWRHQVXUHDÀRZRIUR\DOWLHV
but   quite   possibly   not   strong   enough   to   support   the  
monopoly  model  of  genetic  testing  that  their  vigorous  
patent  enforcement  led  to  from  1998  to  2002,  resulting  
in  Myriad  becoming  the  only  commercial  testing  service  
for  BRCA  mutations  in  the  United  States.  (Myriad’s  U.S.  
business  model  has  not  worked  in  any  other  jurisdiction  
in  the  world,  but  that  is  a  different  story.)  
CAFC  has  sent  a  mixed  message:  yes,  you  can  get  
gene  patents,  but  some  of  the  claims  granted  are  invalid,  
and   some   are   vulnerable   to   challenge   in   subsequent  
cases.  
What  will  happen  now?  There   is   likely   to  be  at  
least  one  more  level  of  appeal  that  could  set  precedent  
on  whether  naturally  occurring  DNA  sequences  can  be  
patented—but  the  real  question  is  how  business  models  
will  adapt.  Only  time  will  tell.
Background
CAFC  hears   all   appeals   on   patent   cases   and   a  
few  other  matters  of  federal  law,  and  CAFC  rulings  set  
nationwide   precedents.  This   is   unusual   compared   to  
most  other  areas  of  law.  There  is  no  equivalent  authority  
below  the  Supreme  Court  for  matters  of  contract  law  
or   tort   law,   for   example.  The   court   can  be  overruled  
by  the  Supreme  Court,  but  otherwise  its  rulings  guide  
jurisprudence  for  all  patent  cases.
Initial  appeals  are  usually  conducted  by  a  three-­
judge  panel  drawn  from  the  full  CAFC  (which  has  a  
chief  judge  and  16  circuit  judges).  In  this  case,  Judges  
Alan  Lourie,  Kimberly  Moore,   and  William  Bryson  
Implementing  this  proposal
In   summary,   we   support   the   creation   of   the  
Across  Disease/Trials  Oversight  Panel   to   assign   and  
prioritize   overall   scientific   objectives   for   the  NCI  
clinical  trials  infrastructure.  We  propose  that  the  current  
Disease-­Specific   Steering  Committees   be   renamed  
WKH'LVHDVH6SHFL¿F6WXG\5HYLHZ&RPPLWWHHV DQG
FRQ¿QH WKHLUDFWLYLWLHV WR VWXG\ UHYLHZDQGDSSURYDO
We  also   request   that   the  Task  Forces  of   the  Steering  
Committees  be  eliminated,  and  replaced  by  new  disease  
VSHFL¿FFRPPLWWHHVWKDWDUHFRQYHQHGE\WKHFRRSHUDWLYH
groups  in  collaboration  with  the  NCI.  Through  this  new  
committee  structure,  the  cooperative  groups  will  work  
together  with  the  NCI  in  a  more  effective  environment  
for  collaborative  study  development,  achieving  the  goals  
of   “information   exchange   at   an   early   stage   of   study  
development”  and  both  cross-­disease  and  within-­disease  
prioritization  of   studies.  With   the   smaller   number   of  
cooperative  groups   resulting   from   implementation  of  
the  IOM  recommendations,  this  goal  is  achievable  as  
never  before.  
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heard  the  case.  Each  of  them  wrote  their  own  analysis—
itself  an  unusual  step—and  the  opinions  run  up  to  105  
pages  of  intricate  technical  and  legal  reasoning.
The   appeal  was   from  a  March   29,   2010   ruling  
by  Judge  Robert  Sweet  in  the  Manhattan,  New  York,  
Federal  District  Court.   Judge  Sweet   declared   invalid  
15  claims  in  7  patents  held  by  Myriad  Genetics.  Claims  
describe  the  boundaries  of  the  intellectual  property  in  a  
patent,  and  notify  others  what  constitutes  infringement.  
Saying  claims  are  invalid  is  to  say  they  should  not  have  
EHHQJUDQWHGE\WKHSDWHQWRI¿FH
Judge  Sweet’s  ruling  was  itself  long  and  complex,  
running  over  150  pages.  The  longest  sections  addressed  
past   jurisprudence  on  patenting  “products  of  nature.”  
His  conclusion  was  that  because  DNA  is  an  embodiment  
of  information,  the  standard  legal  practice  of  claiming  
“isolated”  DNA  did  not  make  DNA  patentable  subject  
matter.  
He  argued  that  “isolated”  DNA  is  not  materially  
different   from   the  DNA   in   its   natural   state.  He   also  
invalidated  some  broad  claims  on  methods  of  comparing  
a  sample  sequence  (from  a  patient  or  from  a  tumor)  to  a  
reference  sequence  of  BRCA1  or  BRCA2  (BRCA1/2)  
and  detecting  differences  (including,  but  not  restricted  
WRFOLQLFDOO\VLJQL¿FDQWPXWDWLRQV$QGKHLQYDOLGDWHG
D¿QDO FRQWHVWHG FODLP FRYHULQJ DQ DVVD\ IRU FDQFHU
therapeutics.  
His  ruling  was  a  surprise  to  most  patent  lawyers  
and   those   in   biotechnology,   as   it   cast   doubt   on   the  
patentability  not  only  of  the  diagnostic  uses  at  issue  in  
this  case,  but  any  patent  on  a  DNA  molecule.
The  case  attracted  29  amicus  curiae  briefs,  “friend  
of   the   court”   advisory  opinions   from  outside   experts  
that  the  court  can  consider  in  making  its  decision.  The  
PRVWVLJQL¿FDQWRIWKRVHEULHIVFDPHIURPWKHVROLFLWRU
JHQHUDOWKHJRYHUQPHQW¶VKLJKHVWRI¿FLDOUHVSRQVLEOH
for  arguing  cases  before  the  Supreme  Court.  
The  solicitor  general  also  made  an  unprecedented  
appearance  before  the  CAFC  at  oral  hearings  on  April  4.  
The  government’s  formal  position  was  that  Judge  Sweet  
was   right—   that  DNA   sequences   as   found   in   nature  
should  not  be  patentable—but  his  ruling  was  too  broad.  
Some  DNA  molecules  are  clearly  man-­made  and  
are  not  found  in  nature—for  example  complementary  
DNA  (cDNA)  molecules  derived  from  mature  messenger  
RNAs  or  engineered  cloning  vectors.  
In  oral  arguments,  the  solicitor  general  suggested  
a  gedanken  experiment:  imagine  a  “magic  microscope”  
that  could  distinguish  between  molecules  found  inside  




is  also  part  of  the  executive  branch,  did  not  agree  with  
this  position.   It  has   issued  many  patents  on  naturally  
occurring  DNA  sequences  and  will  continue  to  do  so  
until  and  unless  a  court  or  Congress  tells  it  otherwise.
What  did  the  Court  decide?
Friday’s   CAFC   ruling   brings   some   clarity   to  
some  questions  of  patent  law,  with  all  three  judges  in  
agreement.  But  there  is  still  residual  disagreement  about  
whether  DNA  molecules  corresponding   to   sequences  
found  in  nature  can  be  patented  or  not.The  disagreement  
about  DNA  as  “found  in  nature”  is  irrelevant  for  most  
biotechnology  applications,  such  as  making  therapeutic  
proteins   or   vaccines,   but   it   is   highly   relevant   for  
diagnostics.  
When  using  DNA  to  make  a  vaccine  or  therapeutic  
protein,  the  DNA  is  valuable  because  it  is  isolated  and  
can   be   used   to  make   a   valuable   end-­product.  When  
making  a  diagnosis,  however,  a   test   is  useful  only   to  
the  extent   it  accurately  replicates   the  sequence  found  
in  nature.  
Judges   Sweet   and  Bryson   (CAFC  dissent)   say  
“no;;”   Judges   Lourie   and  Moore   say   “yes,”   but   for  
somewhat  different  reasons.  Thus,  some  kinds  of  DNA  
diagnostics  are  still  under  a  shadow  of  uncertainty  on  
how  courts  will   interpret   “isolated”   in   the  diagnostic  
FRQWH[W7KDWFRXOGEHFODUL¿HGXSRQIXUWKHUDSSHDORU
it  could  remain  muddy.
The  strength  of  Myriad’s  patent  protection  is  less  
than  it  was.  Myriad  certainly  has  many  patent  claims  
remaining,   but   as   noted   below,   its   broadest  method  
FODLPVZHUHGHHPHGLQYDOLGDQG-XGJH%U\VRQÀDJJHG
problems  with  broad  claims  on  short  DNA  fragments.  
Myriad   certainly   has   strong   rights   on   the   full-­
length   genes   (at   least   on   BRCA1;;   the   history   of  
discovering  BRCA2  is  still  subject  to  dispute).  Myriad’s  
FODLPVRQVSHFL¿FPXWDWLRQVDUHODUJHO\LQWDFWVRDQ\RQH
detecting  one  of  those  mutations  and  reporting  it  to  a  
patient  in  the  U.S.  would  likely  need  a  license.  But  the  
scope  and  strength  of  patent  protection  are  clearly  less  
than  before  the  case  began.
Follow  us  on  Twitter:  @TheCancerLetter
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All  three  judges  agree
All  three  judges  agreed  that:
Some   kinds   of  DNA   can   be   patented,   such   as  
cDNA  molecules  that  are  not  found  in  nature;;
Five  of  the  broadest  method  claims  in  Myriad’s  
patents   are   invalid  because   they  claimed  any  way  of  
comparing  sequences  to  look  for  differences,  a  mental  
act  that  cannot  be  patented;;  and
The  claim  for  an  assay  on  cancer  therapeutics  is  
valid  because  it  entailed  several  “transformative”  steps  
(it  is  not  entirely  clear  why  this  claim  was  in  the  case  at  
DOODQGLWUHFHLYHGYHU\OLWWOHDWWHQWLRQLQWKHEULH¿QJV
or  oral  arguments).
The  patentability  of  DNA  has  been  the  subject  of  
most  headlines  on  the  ruling,  and  indeed  this  was  the  
foremost  worry  of  most  in  industry  and  the  patent  bar.  All  
three  judges  were  quite  clear  that  cDNA  is  patentable.  
cDNA  molecules   encoding  protein   therapeutics   have  
been  among  the  most  valuable  biotechnology  inventions,  
and  the  subject  of  at  least  11  prior  CAFC  decisions.
The  invalidity  of  the  broadest  method  claims  in  
these  patents  is  also  not  a  big  surprise,  and  the  unanimity  
of  the  three  judges  suggests  it  may  become  settled  law  
unless  overturned  on  appeal.  
A  close  reading  suggests  that  the  problem  is  the  
great   breadth   of   the   claims.  This   problem   of   claim  
language  would   be   relatively   easy   to   fix   for   those  
seeking  patent  protection  on  test  methods.  
Judge   Lourie’s  majority   opinion  makes   clear  
that   if   the  claims  had  included  “extracting”  the  DNA  
and  “sequencing”  or  “hybridizing”  it,  rather  than  just  
“comparing”  sample  sequence  to  BRCA1/2  reference  
sequences,   these   claims  would   have   passed  muster.  
Myriad  still  has  hundreds  of  other  claims  in  its  patents.  
While   a   very   large   number   are   irrelevant   for  
diagnostics,  it  only  takes  one  infringed  valid  claim  to  
win  a  case.
Patentability  of  sequences  “found  in  nature”
Most   of   the   prose   in   all   three   judges’   analysis  
focuses   on   the   residual   disagreement   about  whether  
naturally  occurring  DNA  sequences  can  be  patented.  
Judges   Lourie   and  Moore   agreed   that   such  
sequences   are   patentable,   although   their   reasons   are  
somewhat  different.  
Judge  Bryson   dissented,   and   argued   that  DNA  
molecules   corresponding   to  DNA   sequences   found  
in   nature   are   not   patentable.Judge   Lourie   argued  
that   even   naturally   occurring  DNA   sequences   found  
in   chromosomes   are   different   chemicals—different  
molecules—from   the  DNA  molecules  made   in   the  
process  of  diagnostic  testing  and  for  other  purposes.  He  
focused  particularly  on  the  importance  of  the  covalent  
backbone   bonds   being   broken   in   “isolated”  DNA  
compared   to   intact   chromosomal  DNA  containing   a  
gene.  
Judge  Moore  emphasized  the  functional  differences  
of  small  DNA  molecules.  She  also  put  strong  emphasis  
on  not  disrupting  the  practices  and  expectations  that  have  
built  up  in  three  decades  of  DNA  patenting.  
Judges  Moore   and   Lourie   argued   that   any  
categorical  exclusion  from  patentability,  such  as  DNA  
molecules,   should   be   for  Congress   to   enact   through  
statute.  
They  pointed  to  the  bills  proposed  by  Rep.  Xavier  
Becerra   (D-­Calif.)   and   former   Reps.   Lynn  Rivers  
(D-­Mich.)  and  David  Weldon  (R-­Fla.)  as  evidence  that  
Congress  has  explicitly  decided  not  to  do  so  (since  those  
bills  never  even  made  it  to  a  committee  vote).
Judge  Bryson  disagreed  with  the  characterization  
of   “isolated”   as   a  materially   relevant   difference.  He  
argued   that  while  Utah   and  Myriad   scientists   had   to  
ZRUNKDUGWR¿QGWKH%5&$JHQHVDQGWKHLUPXWDWLRQV
“the  genetic  coding  sequence  that  is  the  subject  of  each  
of  the  BRCA  gene  claims  remains  the  same  whether  the  
gene  is  in  the  body  or  isolated,”  and  “the  discovery  of  
the  sequences  is  an  unprotectable  fact.”  
+LVDUJXPHQWDERXWGHIHUHQFHWRWKHSDWHQWRI¿FH
ZDVWKDWWKHRI¿FH¶VGHIHQVHRISDWHQWDELOLW\LQWKH
“utility  guidelines”  was  “perfunctory.”  
He  argued  the  court  should  decide  patentability  just  
as  it  did  in  the  Chakrabarty  case  cited  frequently  by  all  
parties,  in  which  the  Supreme  Court  gave  no  deference  
WRWKHSDWHQWRI¿FHDQGGLGQRWOHDYHLWWR&RQJUHVVWR
decide  if  living  things  could  be  patented.
Judge   Lourie’s   and  Moore’s   arguments   for  
patentability  draw  a  legal  line  between  DNA  molecules  
in   a   cell,   before   isolation,   and   the  DNA  made   in   the  
process  of  sequencing  (or  by  inference,  hybridization)  
methods.  
7KHUHDUH VRPHÀDZV LQ WKHLU ORJLFEDVHGRQD
static  view  of  DNA  as  solely  residing  in  the  form  of  full-­
length  chromosomes.  All  three  judges  talk  of  “isolating  
genes”  but  how  this   is  done   is  exquisitely  dependent  
on  method.  
PCR,  for  example,  “isolates”  DNA  by  amplifying  
only  those  segments  of  DNA  that  have  two  antiparallel  
primer  sequences  and  contiguous  DNA  between  them.  
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Judge  Lourie  puts  great  stock  in  the  fracturing  of  
covalent  bonds  in  the  laboratory  methods  of  “isolation,”  
and  claims  several  times  that  DNA  fragments  would  not  
otherwise  be  found  in  cells.  
Amicus  briefs  at  the  next  level  of  appeal  may  point  
out  that  Arthur  Kornberg  got  a  Nobel  Prize  for  isolating  
fragments  of  DNA  from  inside  cells  and  showing  that  
DNA  replicates  by  stitching  together  short  stretches  of  
newly  synthesized  DNA  fragments  by  ligation.
What  about  the  stuff  that  Rosalind  Franklin  used  to  
take  Photograph  51—which  was  as  isolated  as  they  could  
possibly  make  it  in  1952  for  X-­ray  crystallography—but  
was  nonetheless  presumed  to  capture  DNA  in  its  natural  
naked  essence.  
Oops,  is  that  segment  patentable?  Because  it  sure  
used  the  hand  of  woman  and  was  useful  and  novel  in  
undergirding  one  of   the  major  discoveries  of   the  20th  
century.  
Or  is  it  not  patentable,  because  its  utility  was  not  
UHDOO\ FRPPHUFLDO RU LWZDVPHUHO\ SXUL¿HG RU IRU
some  other  reason?  Hard  to  know.  And  we  never  will  
because  no  one  tried  to  patent  it  then  or  would  do  so  even  
now,  because   its   considerable   utility  was   to   promote  
understanding,  with  little  thought  of  commercialization.
This  may  not  make  a  legal  difference,  since  inside  
the  cell  such  molecules  are  not  “isolated”  in  a  meaningful  
VHQVHEXWWKHGLI¿FXOW\LQGH¿QLQJ³LVRODWHG´FRXOGUDLVH
problems  for  Lourie’s  line  of  reasoning.  
His  privileging  of  the  covalent  bonds  in  the  helical  
backbone  do  not  seem  a  promising  tack,  however.  In  the  
OLVWRIPROHFXOHVRQHZRXOGGH¿QHE\FRYDOHQWERQGV
DNA  would  be  near  the  bottom  of  the  list.  
Hydrogen  bonds  are  the  main  reason  Jim  Watson  
called   his   book  The  Double  Helix,   and   the   reason  
Kornberg’s  DNA   fragments   can   be   ligated   in   their  
proper  chromosomal  position  is  hydrogen  bonding,  not  
covalent  bonds.  
Indeed   the   biological   function   of  DNA  clearly  
depends  on  both  kinds  of  bonds,  and  a  line  that  separates  
“natural”   chromosomal  DNA   and   “unnatural”   and  
patentable  fragments  may  be  harder  to  draw  than  Judge  
Lourie  has  imagined.  
Indeed,  it  is  ironic  that  the  very  genes  patented  here  
are  involved  in  DNA  repair,  and  would  not  be  needed  
at  all  if  Judge  Lourie’s  and  Moore’s  fantasies  of  stable,  
static  chromosomal  DNA  were  the  only  forms  of  DNA  
found  naturally  in  cells.  
Judge  Moore’s  point   that  small  DNA  fragments  
have   utilities   that   natural   DNA   does   not   reveals  
a   different   flaw—all   her   examples   of   detectable  
GLIIHUHQFHVGHSHQGRQFKHPLFDOPRGL¿FDWLRQVWKDWDUH
clearly  man-­made:  to  allow  the  DNA  to  be  detected  (by  
hybridization  or  sequencing).  
Patent  claims  could  cover  those  detectable  man-­
made  molecules  without  involving  the  natural  DNA,  and  
the  border  between  patentable  and  unpatentable  DNA  
would  be  much  easier  to  patrol.  
Myriad  and  many  other  patentholders  have  chosen  
not  to  go  that  route,  presumably  in  order  to  broaden  their  
scope  of  exclusivity.  
Every  general  has  long  known  that  the  longer  the  
fence   the   harder   the   defense.  Whether   stretching   for  
scope  was  wise  or  not  will  now  likely  depend  on  how  
arguments   on   the  meaning  of   “isolated”  play  out   on  
further  appeal.  
Judges  Lourie  and  Moore  did  not  have  the  same  
reasons   for   patentability   of   naturally   occurring  DNA  
sequences,  but  they  did  enjoy  one  joint  celebration.  Both  
hurled  the  solicitor  general’s  magic  microscope  to  the  
ODERUDWRU\ÀRRUZLWKFRQVLGHUDEOHJOHHZKHUHLWQRZ
lies  in  smithereens.  Ouch.
Judge  Bryson’s   argument,   however,   also   has   a  
glaring  weakness.  
His  assertion  that  there  is  no  material  difference  
between  the  natural  chromosomal  DNA  and  the  DNA  
being  sequenced  (or  hybridized)  will  confront  a  strong  
intuition  that  Moore  and  Lourie  appear  to  be  struggling  
to  articulate:  the  only  way  to  detect  a  DNA  fragment  or  
WRVHTXHQFHLWLVWRLVRODWHLWLQVRPHIRUP¿UVW
Judge  Moore   points   out   that   cells   don’t   render  
diagnoses   or   spit   out   sequence   data.  Those   useful  
embodiments   of   genetic   information   clearly   entail  
the   hand   of  woman   or  man.  Does   that  make   them  
patentable?  Perhaps  we  will  see,  behind  the  next  curtain.
Given  that  there  are  weaknesses  in  the  arguments  
on  both  sides,  it  is  not  surprising  that  so  far  the  federal  
judges   confronted  with  DNA  patents   in   a   diagnostic  
context   have   split   2-­2.  The   tie-­breaker  will   probably  
now  await  round  three  on  subsequent  appeal.  
Very   smart   and   thoughtful   people   have   come  
up   against   a   hard   question.  Two   judges   argue   for  
patentability   and   a   magical   word   “isolated”   that  
sometimes  means  isolating  a  gene’s  DNA  from  other  
DNA,  and  sometimes  means  isolating  DNA  from  other  
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cellular  components.  Or  maybe  it  means  isolating  the  
molecule  to  measure  it.  
Using   one   word,   “isolated,”   makes   a   DNA  
molecule   “patentable,”  whereas   inside   a   cell   in   its  
“natural”  state,  it  is  not.  
But   is   that   state  Alaska,  Hawaii,   or   somewhere  
on  the  mainland?  As  part  of  a  complete  chromosome,  
it  is  clear  there’s  agreement  it  is  not  patentable.  But  the  
distinction  between  subchromosomal  fragments  of  DNA  
that  are  natural  and  those  that  are  isolated  amounts  to  a  
tautology:  they’re  isolated  if  you  measure  them.  
Some   in   the  patent   bar   contend   it’s   a  matter   of  
settled  understanding  that  claims  like  Myriad’s  really  
just  pertain  to  the  DNA  actually  derived  from  the  “gene”  
in  question;;  but  these  judges  seem  sometimes  to  be  using  
that  meaning,  but  other  times  not.  Judge  Sweet  called  
the  invocation  of  “isolated”  a  “lawyer’s  trick,”  and  so  
far  the  coherent  rationale  for  showing  him  wrong  is  a  
work  in  progress.  
The  difference  right  now  seems  to  be  “whatever  
they   did   to   detect   the  DNA   in   a   lab   as   opposed   to  
whatever  a  cell  does  with  it.”  And  you  do  the  math.
One  particularly  important  claim—number  16  of  
U.S.  Patent  5,747,282—deals  with  PCR  primers,  and  
would  be  directly  relevant  to  the  way  Myriad  and  most  
laboratories  currently  do  cancer  gene  testing.  That  claim,  
however,  was  not  challenged  in  this  case.
2QH¿QDODVSHFWRIWKH³FRPSRVLWLRQRIPDWWHU´
claims  may  prove  important,  but  will  require  a  different  
case  to  be  litigated.  
Judge  Bryson  took  particular  pains  to  suggest  that  
the  claims  to  small  DNA  fragments,  as  short  as  15  base  
pairs,  would   confront   serious  problems  because   they  
“hit”  many  other  genes  in  the  genome,  suggesting  they  
would  not  meet  the  “novelty”  criterion  for  patenting.  
He  also  noted  that  Myriad  could  have  been  much  
PRUHVSHFL¿FLQGHVFULELQJWKHPROHFXOHVWKH\DFWXDOO\
LGHQWL¿HGDQGFKDUDFWHUL]HGUDWKHUWKDQFODLPLQJJHQHULF
very  broad  categories  of  DNA  molecules  that  go  well  
beyond  what  they  actually  characterized  in  the  patent.  
+H MXGJHV FODLPV¿YH DQG VL[ LQYDOLG EHFDXVH
the   sweep  of   the   claims   includes   naturally   occurring  
sequences   and   not   just   DNA  molecules  markedly  
different   from   and  with   uses   distinct   from  naturally  
occurring  sequences.  And  if  Myriad  were  to  lose  these  
claims,  his  view  appears  to  be  it  is  their  own  damn  fault  
for  overreaching.  
His   logic   also   suggests   these   claims   would  
vulnerable  on  two  other  criteria:  enablement  (whether  
someone   skilled   in   the   art   could  make   and   use   the  
invention)   and  written   description   (whether   it   has  
been  described  precisely  in  the  patent).  These  aspects  
of   patentability  were   never   argued   in   district   court,  
so   they  cannot  be  decided  on  appeal  and  will  not  be  
directly  decided  in  this  case.  Judge  Bryson’s  comments  
nonetheless   flag   the   vulnerability   of   some   claims  
relevant  to  DNA  diagnostics.
These  “short  sequence”  claims  matter  because  they  
are  broad  claims  that  could  block  full-­genome  sequence  
analysis  and  many  methods  of  genetic  testing.  
If  they  are  invalid,  a  careful  legal  analysis  might  
¿QGPRUH IUHHGRP WR RSHUDWHZLWKRXW LQIULQJHPHQW
liability  than  had  been  assumed  before  Myriad’s  patent  
claims  were  challenged,  and  not  just  for  BRCA1/2,  but  
for  a  welter  of  other  gene  patents  with  similar  patent  
claim  structure.  
Such  patents  are  not  uncommon,  and  have  been  
vigorously  enforced  not  only  by  Myriad,  but  also  by  
$WKHQD'LDJQRVWLFVDQGRWKHU¿UPVHQJDJHGLQJHQHWLF
testing.  While  this  section  of  Judge  Bryson’s  ruling  is  
not   binding,   it   does   signal   that   some  of   the  broadest  
claims  that  have  been  enforced  against  genetic  testing  
laboratories  might   fall   if   challenged,   or  might   be  
QDUURZHG XQGHU UHH[DPLQDWLRQ LQ OLJKW RI WKH ¿QDO
decision  in  this  case.  
It  would  not  be  surprising  to  see  these  sections  of  
Judge  Bryson’s  dissent  appear  in  future  cases  that  push  
back  against  enforcement  of  gene  patents  for  diagnostic  
use.  But  some  testing  laboratory  somewhere  would  need  
to  take  a  big  risk  in  pushing  back.
Standing  to  sue
0\ULDG¶V¿UVWDUJXPHQWZDVWKDWWKHSODLQWLIIVKDG
no  standing  to  sue.  
The   three   judges   agreed   that  only  one  plaintiff,  
Harry  Ostrer   of  New  York  University,   had   standing.  
0\ULDGKDGVHQWKLPDQRWL¿FDWLRQOHWWHULQDQG
when  he  was  precluded   from  sending  samples   to   the  
University   of   Pennsylvania,   he   reluctantly   started  
sending  samples  to  Myriad  for  testing.  
He   made   a   clear   statement   that   he   would  
immediately   offer  BRCA   testing   if   the   patents  were  
invalidated.  The  University  of  Pennsylvania  had  also  
JRWWHQQRWRQO\DQRWL¿FDWLRQ OHWWHUEXWDOVRDFHDVH
and-­desist  letter  from  Myriad,  and  indeed  was  sued  by  
Myriad  before  agreeing  to  stop  doing  BRCA  testing  for  
anyone  other  than  University  of  Pennsylvania  patients.  
In  a  passage  that  must  be  an  embarrassment  for  
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whomever  drafted  their  letters,  two  potential  plaintiffs,  
Haig  Kazazian   and  Arupa  Ganguly,  would   have   had  
standing  to  sue,  except  that  their  statements  of  intent  hid  
behind  legal  weasel  words—indicating  only  that  they  
ZRXOGFRQVLGHUWHVWLQJQRWDI¿UPLQJWKH\ZRXOGGRVR
They  and  all  other  plaintiffs  except  Ostrer  were  
denied  standing.  Perhaps  someone  at  UPenn  can  learn  
a  lesson  about  bad  lawyering,  and  when  preserving  your  
options  defeats  your  purpose.
At  the  eleventh  hour,  Myriad  challenged  Ostrer’s  
standing  because  of   his   impending  move   to  Einstein  
University.   On   the   same   date   that   the   ruling  was  
published,  the  ACLU  countered  with  a  letter  to  the  court  
DI¿UPLQJWKDW2VWUHU¶VMREFKDQJHGLGQRWFKDQJHKLV
intentions  or  ability  to  do  BRCA  testing,  and  so  should  
not  affect  standing.  
This  is  a  matter  that  will  be  raised  in  the  next  level  
of  appeals  if  it  still  appears  relevant.
What  a  weird  case
Most  of  the  legal  analysis  has  been  framed  as  a  
matter  of  patent  law,  and  most  of  the  arguments  have  
been  crafted  to  create  precedent  in  patent  jurisprudence.  
This  is  not  a  typical  patent  case,  however.  The  case  
has  had  very  little  apparent  impact  on  Myriad’s  business  
practices.  Myriad  raised  its  prices  for  the  BRCAnalysis®  
test  just  days  after  Judge  Sweet’s  ruling  in  March  2010.  
That  one   test  generated  88  percent  of  Myriad’s  $102  
million   revenues   last   quarter,   and   testing  was   up   9  
percent.  Myriad’s  cash  cow  has  at  least  postponed  its  
date  at  the  abattoir.
One  practical  implication  of  the  CAFC  ruling  may  
be   resumption  of   patent   enforcement   against   genetic  
testing   laboratories.   I   have   already  gotten   one   email  
from  a  laboratory  director  who  states  that  he  has  gotten  
a   “barrage”  of   letters   from  patentholders   in   the  days  
after  the  ruling.  
,IVR WKLVFRXOGLQYLWHDÀXUU\RIQHZOLFHQVLQJ
deals,   but   it   could   also   induce   a   push-­back   from  
laboratories   doing   genetic   testing  who   read   Judge  
Bryson’s  dicta  about  the  vulnerability  of  the  broadest  
claims.  
If  the  judge  is  right,  then  laboratories  could  prevail  
in   court,   invalidate   claims   blocking   diagnostic   uses,  
free   up   some   forms   of   diagnostic   testing,   and  make  
enforcement  of  broad  diagnostic  claims  expensive  and  
GLI¿FXOW
Sending   letters   is   relatively   easy   and   cheap—
prevailing  with   a   vulnerable   patent   in   court   is   not.  
Myriad  is  a  case  in  point.  
And  it  is  hard  to  know  if  ACLU  and  PubPat  would  
stand  ready  to  assist   laboratories  who  decide   to  push  
back  against  a  new  wave  of  patent  enforcement  efforts.  
Both  sides  are  at  risk  of  overplaying  their  hands.  (Again,  
this  is  a  regular  refrain  in  many  patent  cases.)
This  case  was  brought  for  policy  purposes.  Most  of  
the  original  plaintiffs  were  people  who  would  otherwise  
be  Myriad’s  customers  (and  some  of  them  still  are).  
Only  a  few  were  potential  competitors,  and  one  of  
those  was  the  only  plaintiff  that  the  CAFC  left  standing  
with  standing.
7KHSXUSRVHRI¿OLQJWKHODZVXLWZDVWRFKDOOHQJH
gene   patents.   It   has   succeeded   in   driving   public  
discussion   of   the   issues  well   beyond   any   previous  
debate,  and  it  has  engaged  constituencies  well  beyond  
industry  and  the  patent  bar.  That  may  be  this  case’s  most  
lasting  legacy.
A  simple  “what  if”  story  suggests  that  the  case  is  
not  entirely  about  patenting  per  se,  but  as  much  or  more  
about  how  exclusive  patent  rights  are  used.  
Suppose   that  Mary-­Claire  King   had  won   the  
UDFHWR¿QG%5&$  The  gene  would  likely  have  been  
patented  by  the  University  of  California  or  University  of  
Washington,  just  as  her  discovery  of  a  genetic  linkage  to  
markers  on  chromosome  17  was  patented  and  licensed.  
Indeed,  given  the  plausible  role  for  gene  transfer  
and  the  possible  therapeutic  use  of  the  encoded  protein  
that  many  postulated  at   the   time,   it  would  have  been  
irresponsible  not   to  patent   the  gene,   in  case   it  would  
require   substantial   subsequent   private   investment   to  
translate   the   discovery   into   a   therapeutic.  But   there  
would  probably  not  have  been  a  furor  comparable   to  
what  arose  with  the  Myriad  patents,  and  almost  certainly  
no  suit  like  that  working  its  way  through  appeal.  
Dr.  King  would  likely  have  engaged  breast  cancer  
advocates  in  thinking  through  patenting  and  licensing.  
This  case  is  as  much  or  more  about  business  practices  as  
it  is  about  patent  law  (of  course,  many  patent  cases  are).
0\ULDG UXQV D KLJKO\ HI¿FLHQW ODERUDWRU\ZLWK
excellent   turnaround  time  and  clearly  written  clinical  
interpretations.   It   sets   a   standard   for   securing   third-­
party  payment  of  an  expensive  genetic   test,   reducing  
the  payment  burden  on  those  getting  tested.  It  won  an  
LQWHQVHDQGGLI¿FXOWUDFHWR¿QGWKH%5&$JHQHDQG
the  BRCA2  race  ended  in  a  dead  heat.  
Myriad  should  be  an  ally  and  hero  of  the  breast  
cancer  movement.  But  it  is  not.  
Indeed,  the  organization  representing  those  with  
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the  most  to  gain  from  tests  to  assess  inherited  cancer  
risk—and   thus   logically  Myriad’s   best   buddy   in   the  
WUHQFKHV¿JKWLQJDJDLQVWFDQFHU²LV)DFLQJ2XU5LVN
of  Cancer  Empowered  (FORCE),  which  supported  the  
plaintiffs  (although  it  was  not  a  plaintiff  itself).  
Exactly  how  and  why  Myriad  alienated  its  natural  
allies  may   eventually  make   this   a   teaching   case   for  
business  schools.  This  patent  lawsuit  is  another  chapter  
in  that  story.
Next  steps
Both  sides  in  this  case  have  something  to  appeal,  
and  one  or  both  sides  may  well  do  so.  Myriad  could  
appeal   the   invalidation   of   its  method   claims;;  ACLU  
and  PubPat  seem  likely  to  appeal  in  hopes  that  Judge  
Bryson’s  dissent  might  become  the  majority  opinion  of  
the  CAFC  or  the  Supreme  Court.  
Either  side  can  petition  the  entire  CAFC  to  hear  the  
case  “en  banc.”  The  case  could  also  go  to  the  Supreme  
Court.  Either  the  entire  CAFC,  the  Supreme  Court,  or  
both  could  decide  to  hear  the  case.  
The  next  steps  are  at  the  discretion  of  the  courts  
WKLV¿UVW OHYHORIDSSHDOZDVQRWGLVFUHWLRQDU\7KH
immense  amount  of  public  attention,   the  entry  of   the  
solicitor  general   into   the  case,   the  number  of  amicus  
briefs,   the   presence   of   a   very   long   district   court  
opinion,  and  three  CAFC  judges’  arguments  that  show  
sharp  disagreement  about  the  patentability  of  naturally  
occurring  DNA   sequences,   all   suggest   that   Friday’s  
ruling  may  not  be  the  last  court  decision  in  this  case.
,QD¿QDO LURQ\ WKH MXGLFLDOSURFHVV LV LQDUDFH
with  patent  expiration.  
7KHODZVXLWZDV¿OHGLQ0D\DQGGHFLGHGLQ
GLVWULFWFRXUWLQ0DUFK7KLV¿UVW&$)&GHFLVLRQ
was  handed  down  in  late  July  2011.  
The   next   appeal,   if   granted,   would   likely   be  
decided   in   2012,   and   if   there   is   a   subsequent   appeal  
WRWKH6XSUHPH&RXUWD¿QDOFRXUWGHFLVLRQFRXOGEH
handed  down  just  a  year  or  two  before  the  broadest  and  
most  important  BRCA  patents  begin  to  expire  in  2014  
and  2015.
[For   those   interested   in   background  documents  
DQGRWKHUGHWDLOVDERXW WKLVFDVHRU¿QGLQJD OLQN WR
a   parallel   case   that  will   go   to   trial   later   this   year   in  
Australia,   see   http://www.genome.duke.edu/centers/
gelp/Myriad/index.php]
Funding  Opportunity:
DoD  Offering  $150  Million
For  Breast  Cancer  Research
THE  DEPARTMENT  OF  DEFENSE  Breast  
Cancer  Research  Program  is  providing  $150  million  
to   support   “innovative,   high-­impact”   breast   cancer  
research  through  a  series  of  grants  and  awards.
The  Clinical  Translational  Research  Award  
SURYLGHVPD[LPXP¿QGLQJRI PLOOLRQ IRU GLUHFW
costs.   Investigators  must   be   at   or   above   the   level   of  
assistant  professor  and  preliminary  data  is  required.
The  award  supports  research  with  a  potential  for  
GLUHFW FOLQLFDO EHQH¿WV DQG VLJQL¿FDQW LPSURYHPHQWV
in  current  breast  cancer  prevention  or   therapy.  Phase  
I   of   the   award  will   enable   completion   of   preclinical  
translational  studies  and  possible  FDA  approvals.  Phase  
II  will  begin  and  carry  out  the  clinical  trial.
The  Impact  Award  offers  $2  million  in  funding  
for  direct  costs.  This  award  supports  unique  research  
SURMHFWVWKDWIRFXVRQVFLHQWL¿FDQGFOLQLFDOEUHDVWFDQFHU
issues,  with  an  aim  to  revolutionizing  patient  care  and  
therapy.  Applications   that   focus   on   less   explored   or  
poorly  understood  areas  are  strongly  encouraged.  
Pre-­proposals  for  either  award  are  due  before  Sept.  
20.  Full  application  submission  is  by  invitation  only.
Application  instructions  are  available  for  download  
from  www.grants.gov.    
A  listing  of  all  US  Army  Medical  Research  and  
Materiel   Command   funding   opportunities   can   be  
obtained  on   the  Grants.gov  website   by   searching   for  
CFDA  Number  12.420.
The  pre-­application  must  be  submitted  through  the  
2I¿FHRI&RQJUHVVLRQDOO\'LUHFWHG0HGLFDO5HVHDUFK
Programs  eReceipt  website  (http://cdmrp.org).
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Find  subscription  plans  by  clicking  Join  Now  at:  
http://www.cancerletter.com/
